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Abstract: BACKGROUND The suture-tendon interface is often the weakest link in tendon-to-tendon or
tendon-to-bone repair. Genipin is an exogenous collagen crosslink agent derived from the gardenia fruit
that can enhance suture force to failure of the tendon-suture interface. Viable methods for intraoperative
clinical delivery of genipin could be of clinical utility, but to our knowledge have not yet been extensively
studied. QUESTIONS/PURPOSES The purposes of this study were (1) to evaluate whether sutures
precoated with genipin can augment the suture-tendon interface to improve force to failure, stiffness, and
work to failure in healthy and degenerated tendons; and (2) to determine the effect of genipin on the extent
and distribution of crosslinking. METHODS Single-stitch suture pullout tests were performed ex vivo on
25 bovine superficial digital flexor tendons. To assess effects on native tissue, one group of 12 tendons was
cut in proximal and distal halves and randomized to treatment (n = 12) and control groups (n = 12) in a
matched-pair design. One simple stitch with a loop with either a normal suture or genipin-coated suture
was applied to tendons in both groups. To simulate a degenerative tendon condition, a second group of
13 tendons was cut in proximal and distal halves, injected with 0.2 mL of collagenase D (8 mg/mL) and
incubated for 24 hours before suturing with either a genipin-coated suture (n = 13) or their matched
controls (n = 13). Sutures from all groups then were loaded to failure on a universal materials testing
machine 24 hours after suturing. Suture pullout force, stiffness, and work to failure were calculated from
force-displacement data and compared between the groups. Additionally, fluorescence was measured to
determine the degree of crosslinking quantitatively and a qualitative analysis of the distribution pattern
was performed by microscopy. RESULTS In healthy tendon pairs, the median maximum pullout force was
greater with genipin-coated sutures than with control sutures (median, 42 N [range, 24-73 N] versus 29 N
[range, 13-48 N]; difference of medians, 13 N; p = 0.003) with corresponding increases in the required work
to failure (median, 275 mJ [range, 48-369 mJ] versus 148 mJ [range, 83-369 mJ]; difference of medians,
127 mJ; p = 0.025) but not stiffness (median, 4.1 N/mm [range, 2.3-8.1 N/mm] versus 3.3 N/mm [range,
1.1-9.6 N/mm]; difference of medians, 0.8 N/mm; p = 0.052). In degenerated tendons, median maximum
pullout force was greater with genipin-coated sutures than with control sutures (median, 16 N [range,
9-36 N] versus 13 N [range, 5-28 N]; difference of medians, 3 N; p = 0.034) with no differences in work
to failure (median, 75 mJ [range, 11-249 mJ] versus 53 mJ [range, 14-143 mJ]; difference of medians, 22
mJ; p = 0.636) or stiffness (median, 1.9 N/mm [range, 0.7-13.4 N/mm] versus 1.6 N/mm [range, 0.5-5.6
N/mm]; difference of medians, 0.3 N/mm; p = 0.285). Fluorescence was higher in tendons treated with
genipin-coated sutures compared with the control group, whereas higher fluorescence was observed in the
treated healthy compared with the degenerated tendons (difference of means -3.16; standard error 1.08;
95% confidence interval [CI], 0.97-5.34; p = 0.006/healthy genipin: mean 13.04; standard error 0.78; 95%
CI, 11.47-14.62; p < 0.001/degenerated genipin: mean 9.88; SD 0.75; 95% CI, 8.34-11.40; p < 0.001).
DOI: https://doi.org/10.1007/s11999.0000000000000247





Camenzind, Roland S; Tondelli, Timo O; Götschi, Tobias; Holenstein, Claude; Snedeker, Jess G (2018).
Can Genipin-coated Sutures Deliver a Collagen Crosslinking Agent to Improve Suture Pullout in Degener-
ated Tendon? An Ex Vivo Animal Study. Clinical Orthopaedics and Related Research, 476(5):1104-1113.
DOI: https://doi.org/10.1007/s11999.0000000000000247
2
Clin Orthop Relat Res (2018) 476:1104-1113
DOI 10.1007/s11999.0000000000000247
Basic Research
Can Genipin-coated Sutures Deliver a Collagen Crosslinking
Agent to Improve Suture Pullout in Degenerated Tendon? An Ex
Vivo Animal Study
Roland S. Camenzind MD, Timo O. Tondelli PhD, Tobias Götschi, Claude Holenstein, Jess G. Snedeker PhD
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Abstract
Background The suture-tendon interface is often the
weakest link in tendon-to-tendon or tendon-to-bone repair.
Genipin is an exogenous collagen crosslink agent derived
from the gardenia fruit that can enhance suture force to
failure of the tendon-suture interface. Viable methods for
intraoperative clinical delivery of genipin could be of
clinical utility, but to our knowledge have not yet been
extensively studied.
Questions/purposes The purposes of this study were (1)
to evaluate whether sutures precoated with genipin can
augment the suture-tendon interface to improve force to
failure, stiffness, and work to failure in healthy and de-
generated tendons; and (2) to determine the effect of
genipin on the extent and distribution of crosslinking.
Methods Single-stitch suture pullout tests were performed
ex vivo on 25 bovine superficial digital flexor tendons. To
assess effects on native tissue, one group of 12 tendons was
cut in proximal anddistal halves and randomized to treatment
(n = 12) and control groups (n = 12) in amatched-pair design.
One simple stitch with a loop with either a normal suture or
genipin-coated suture was applied to tendons in both groups.
To simulate a degenerative tendon condition, a second group
of 13 tendons was cut in proximal and distal halves, injected
with 0.2 mL of collagenase D (8 mg/mL) and incubated for
24 hours before suturing with either a genipin-coated suture
(n = 13) or their matched controls (n = 13). Sutures from all
groups then were loaded to failure on a universal materials
testing machine 24 hours after suturing. Suture pullout force,
stiffness, and work to failure were calculated from force-
displacement data and compared between the groups.
Additionally, fluorescence was measured to determine the
degree of crosslinking quantitatively and a qualitative anal-
ysis of the distribution patternwas performed bymicroscopy.
Results In healthy tendon pairs, the median maximum
pullout force was greater with genipin-coated sutures than
with control sutures (median, 42 N [range, 24–73 N] versus
29 N [range, 13–48 N]; difference of medians, 13 N; p =
0.003) with corresponding increases in the required work to
failure (median, 275 mJ [range, 48–369 mJ] versus 148 mJ
[range, 83–369 mJ]; difference of medians, 127 mJ; p =
0.025) but not stiffness (median, 4.1 N/mm [range, 2.3–8.1
N/mm] versus 3.3 N/mm [range, 1.1–9.6 N/mm]; difference
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of medians, 0.8 N/mm; p = 0.052). In degenerated tendons,
median maximum pullout force was greater with genipin-
coated sutures than with control sutures (median, 16 N
[range, 9-36 N] versus 13 N [range, 5-28 N]; difference of
medians, 3 N; p = 0.034) with no differences in work to
failure (median, 75 mJ [range, 11–249 mJ] versus 53 mJ
[range, 14–143mJ]; difference ofmedians, 22mJ; p = 0.636)
or stiffness (median, 1.9 N/mm [range, 0.7–13.4 N/mm]
versus 1.6 N/mm [range, 0.5–5.6 N/mm]; difference of
medians, 0.3 N/mm; p = 0.285). Fluorescence was higher in
tendons treated with genipin-coated sutures compared with
the control group, whereas higher fluorescence was observed
in the treated healthy comparedwith the degenerated tendons
(difference of means -3.16; standard error 1.08; 95% confi-
dence interval [CI], 0.97–5.34; p = 0.006/healthy genipin:
mean 13.04; standard error 0.78; 95% CI, 11.47-14.62; p <
0.001/degenerated genipin: mean 9.88; SD 0.75; 95% CI,
8.34-11.40; p < 0.001).
Conclusions Genipin-coated sutures improved force to
failure of a simple stitch at the tendon-suture interface in
healthy and degenerated tendons in an ex vivo animal
model. Fluorescence was higher in tendons treated with
genipin-coated sutures compared with the control group.
Clinical Relevance A genipin-coated suture represents
a potential delivery vehicle for exogenous crosslink agents
to augment suture retention properties. In vivo animal
studies are the next logical step to assess safety and efficacy
of the approach.
Introduction
Tendon injuries are common and often result in surgical
repair using open or arthroscopic means, but these repairs do
not always heal. Followup studies suggest that between 13%
and 68% of patients who undergo rotator cuff repair have
retears [19, 21–23, 26, 31, 41] with suture cut-through con-
stituting the most common failure mode [3, 11]. The causes
of retears are multifactorial and more frequently occur in the
older patient [25]. Age-related degenerative changes of the
rotator cuff [40, 42, 46] likely play a role. Such degeneration
histologically presents with disorientation and thinning of
collagen fibers and reduced collagen content [24, 34].
To overcome the limitations imposed by weakened
tissue structures that undergo repair, approaches to im-
prove the mechanical stability of the initial surgical repair
have been proposed. These include improved stitch con-
figuration [9, 21], tendon grasping techniques [2, 29], and
tissue augmentation by incorporating reinforcing materials
such as human dermal allograft [5]. Another possible tissue
augmentation technique is application of exogenous
crosslinking agents with the aim to strengthen the tissue
surrounding the suture and thereby increase resistance to
suture cut-through. Crosslinking agents have been reported
to increase the tensile strength of tendon tissue up to 110%
[17]. Genipin is a naturally occurring crosslinking agent
derived from Gardenia jasminoides (an evergreen flower-
ing plant) with relatively low cytotoxicity [15-17]. Genipin
has emerged as a promising candidate for preclinical in-
vestigation with results of an earlier study showing po-
tential to increase suture-tendon force to failure in an ex
vivo sheep model [10]. In that study, sheep infraspinatus
tendons were incubated in a 20-mmol/L genipin solution
for 24 hours; this process increased the maximum suture
pullout force of a single suture stitch by 30%. Preliminary
work has shown that embedding the crosslinking agent in
the suture may enhance tissue delivery [38], although the
utility of this approach for arthroscopic repair of torn ten-
dons with underlying tissue degeneration remains unin-
vestigated, to the best of our knowledge [38]. The aim of
the current investigation was to assess the potential of
a genipin-releasing suture to augment suture retention
strength using a simple stitch configuration in healthy and
degenerative tissues, whereby tendon degeneration was
modeled through collagenase injection to disrupt the col-
lagen matrix [7, 14, 27, 43].
Specifically, we sought (1) to evaluate whether sutures
precoated with genipin can augment the suture-tendon in-
terface to improve suture force to failure, stiffness, and
work to failure in healthy and degenerated tendons; and (2)
to determine the effect of genipin on the extent and dis-
tribution of crosslinking.
Materials and Methods
A total of 25 superficial digital flexor tendons from ap-
proximately 2-year-old cattle were obtained from a local
abattoir. These freshly harvested tendons were grossly
examined for pathologies, wrapped in gauze, moistened
with phosphate-buffered saline (PBS) solution, and stored
at -20° C until testing.
Preparation of Suture Coating
Suture coating was prepared according to the description of
Sundararaj et al. [38]. The formula consists of a genipin-
cosolvent solution with dimethyl sulfoxide (Sigma-Aldrich,
St Louis, MO, USA) and acetone (50:50 v/v). Genipin (500
mg/mL) (Challenge Bioproducts Co, Ltd, Taiwan, Republic
of China) was added to the cosolvent solution. Acid end-
capped poly(lactic-co-glycolic acid) (Akina, Inc, West
Lafayette, IN, USA) with a lactic acid:glycolic acid ratio of
50:50 and polyethylene glycol (Mn 400)was dissolved in the
genipin-cosolvent solution at 1% and 35%, respectively, to
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form the coating formulation. High-strength braided poly-
ethylene suture (ORTHOCORD® USP #2; DePuy Synthes,
New Brunswick, NJ, USA) was submerged in the coating
solution for 10 minutes. In modification of the protocol
proposed by Sundararaj et al. [38], soaked sutures were not
air-dried but vacuum-dried for 2 hours to ensure complete
evaporation of the solvent.
Tendon Preparation
Before testing, tendon explants were thawed, cut in prox-
imal and distal equally sized halves, and randomly allo-
cated to the specific test group in a matched-pair design.
The samples of the degenerated testing group were injected
with 0.2 mL collagenase D (Roche Diagnostics GmbH,
München, Germany) in PBS (8 mg/mL) at the site of
subsequent repair 24 hours before suturing. This tendon
degeneration protocol was established in a preliminary
experiment and has been used with similar dosage in pre-
vious in vivo [33, 43, 44] and ex vivo [7, 14] work. All
tendons were wrapped in gauze moistened with PBS and
stored at room temperature for 24 hours. Either a 14-cm
long untreated (Fig. 1A) or genipin-coated suture (Fig. 1B)
was inserted with a simple stitch into the tendon at a dis-
tance of 10 mm from the tendon end and tied in a single-
loop configuration with two sliding half hitches followed
by alternating half hitches for a total of seven throws. After
suturing, all tendons were wrapped in gauze moistened
with PBS and stored at room temperature for 24 hours until
mechanical testing.
Mechanical Testing of Suture Pullout
The tendon ends were wrapped in PBS-soaked pieces of
cloth and fixed in clamps [14]. Cyanoacrylate adhesive was
used to reduce slippage. The suture loop then was con-
nected to a 1-kN load cell (GTM Gassmann Theiss Mes-
stechnik GmbH, Bickenbach, Germany) of a universal
materials testing machine (Zwick 010; Zwick GmbH, Ulm,
Germany) (Fig. 1A-B). Specimens were preloaded at 5 N
for 1 minute and then loaded to failure with a force in-
crement of 1 N per second [10]. Force (N) and displace-
ment (mm) were recorded with dedicated software
(testExpert® 10; Zwick-Roell, Ulm, Germany). The sam-
ples were sprayed intermittently with PBS during mea-
surement to prevent drying.
Data Analysis of Mechanical Testing
For data analysis, a corrected force-displacement signal
was used. In a separate mechanical test, the force-
displacement behavior of only the suture loop was recor-
ded. This force-displacement behavior was then subtracted
from the force-displacement data of the current experi-
ments to yield a signal irrespective of suture strain
(Fig. 1C).
Stiffness and work to failure calculations were based on
the transformed data. Force to failure was defined as the
maximum force achieved. Stiffness (N/mm)was calculated
as the slope of the linear curve from 5 N to maximum force.
Work to failure (mJ) was computed from the end of preload
(5 N) to maximum load.
Optical Spectral Properties
Normally opaque collagen tissue turns blue (ie, absorbs
light at 590 nm) after exposure to genipin and these
crosslinks emit fluorescence at 645 nmwhen excited at 590
nm [1, 30, 37]. These specific optical properties were used
to determine the amount and distribution pattern of
genipin-induced crosslinks. For this purpose, after me-
chanical testing, a total of seven tissue extracts of ap-
proximately 60 mg were taken at increasing distances from
the location of the suture entrance in 3-mm increments
(Fig. 2). The tissue samples were lyophilized for at least 6
hours (Alpha 2-4 LSCplus; Martin Christ Gefrier-
trocknungsanlagen GmbH, Osterode am Harz, Germany)
and dry weight was recorded. Subsequently, the tissue
samples were digested for 72 hours in 0.6 mg/mL papain in
0.9 mL of an EDTA disodium salt solution (100 mM so-
dium phosphate buffer/10 mM Na2EDTA) at 65° C [35].
After digestion, samples were centrifuged at 8000 relative
centrifugal force for 1 hour. Three aliquots per sample were
pipetted on a 96-cell culture well-plate (Thermo Fisher
Scientific, Waltham, MA, USA). A fluorescence assay was
performed at 590 nm excitation and 645 nm emission
wavelength (SpectraMax®GeminiXS; Molecular Devices,
LLC, Sunnyvale, CA, USA). Absorption was recorded
with a spectrophotometer (Epoch; BioTek Instruments
GmbH, Luzern, Switzerland) for wavelengths from 380 to
700 nm at 10-nm increments. To yield a measure for
genipin-specific optical properties, fluorescence and ab-
sorption readouts were standardized by dry weight and
readouts of the healthy untreated tendons at the suture in-
sertion site. Hence, fluorescence and absorption outcome
measures are relative to untreated tendons and have no unit
of measurement.
Microscopy
To qualitatively assess the spatial fluorescence emission of
genipin-induced crosslinks, confocal image acquisition
was performed using an inverted spinning disc confocal
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microscope (iMic; FEIMunich GmbH,Munich, Germany)
using a 4x (0.16 NA) objective (OlympusTMUPlan S-Apo;
Thermo Fisher Scientific) and a Hamamatsu Orca®-flash
4.0 V2 Digital CMOS camera C11440-22CU (Hamamatsu
Photonics KK, Hamamatsu City, Japan). Genipin cross-
linked tendon samples were mounted in a 30-mm petri dish
and submerged in 1x PBS during imaging. A laser exci-
tation wavelength of 405 nm was used to observe the
autofluorescence of collagen type I [20] and the genipin-
induced crosslinking was imaged with an excitation
wavelength of 560 nm. Single z-stacks were acquired
covering the whole length of the sample and subsequently
tiled using the embedded function of Live acquisition
Software, Offline Analysis application (FEI Munich
GmbH, Munich, Germany). Final image processing
(maximum intensity projection and composite) was done
using ImageJ (https://imagej.nih.gov/ij/).
Statistical Analyses
As a result of the matched-pair design, mechanical data of
uncoated and genipin-coated sutures were analyzed using
ratio t-tests. According to D’Agostino’s K-squared test
[12], the ratios of treated to control for all mechanical
variables were normally distributed. The significance level
was set at 0.05 and the results are reported as medians and
range if not stated otherwise. All significance tests were
two-sided. One-way analysis of variance and t-tests were
used to analyze differences in the level of absorption and
fluorescence across groups. The longitudinal distribution
pattern of fluorescence and absorption was analyzed by
linear regressions using fluorescence as the dependent
variable and distance from the suture as well as group as
a dummy-coded independent variable. The regression
coefficients reflect the difference in percent along the ten-
don and across groups. The statistical analyses and graphs
were computed using MATLAB® (MATLAB® and Sta-
tistics ToolboxTMRelease 2016b;MathWorks, Inc, Natick,
MA, USA), GraphPad Prism® 7.02 for Windows (Graph-
Pad Software, La Jolla CA, USA), or Stata® 14.0 for
Windows (StataCorp LP, College Station, TX, USA).
Results
Genipin-loaded Sutures Showed Improved
Pullout Characteristics
Median force to failure in a healthy tendon with a genipin-
coated suture was 42 N (range, 24–73 N) compared with 29
N (range, 13–48 N) in the control group (difference of
medians, 13; p = 0.003) (Fig. 3). In the tendons pretreated
Fig. 1 A-C The experimental setup used to measure the tendon-suture pullout force is
shown. (A) A single-loop stitch with an untreated suture was performed in a bovine su-
perficial digital tendon. (B) The tendon was blue after 24 hours of exposure to a genipin-
coated suture. (C) Single-loop curves for measurement of maximumpullout force (Fmax) are
shown. Suture deformation as a function of force-displacement (gray dashed line) thenwas
subtracted from the raw signal (black dashed line) so that the computed signal solely
reflects force displacement of the suture in the tissue (red solid line).
Fig. 2 Tissue samples of approximately 60 mg were taken at
the suture canal and longitudinal to the tendon in both
directions in 3-mm increments, yielding a total of seven tissue
extracts per tendon sample for fluorescence assay.
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with collagenase, median force to failure with a genipin-
coated suture was 16 N (range, 9-36 N) compared with 13
N (range, 5-28 N) in the control group (difference of
medians, 3; p = 0.034). No difference in stiffness with the
numbers available was detected in the healthy tendons (4.1
N/mm [range, 2.3-8.1 N/mm] versus 3.3 N/mm [range,
1.1-9.6 N/mm]; differences of medians, 0.8; p = 0.052) nor
in the degenerated tendons (1.9 N/mm [range, 0.7-13.4
N/mm] versus 1.6 N/mm [range, 0.5-5.6 N/mm]; differ-
ence of medians, 0.3; p = 0.285) (Fig. 4A-B). Genipin
coating increased the work to failure in the healthy tendons
(275 mJ [range, 48-369 mJ] versus 148 mJ [range, 83-369
mJ]; difference of medians, 127; p = 0.025), but with the
numbers available, we observed no difference in work to
failure in the degenerated tendons (75 mJ [range, 11-249
mJ] versus 53 mJ [range, 14-143 mJ]; difference of
medians, 22; p = 0.636) (Fig. 4C-D). The failure mode in
all tests was suture cutting through the tendon in all cases.
Comparing the two control groups (healthy tendons with
uncoated sutures versus degenerated tendons with un-
coated sutures), decreases in force to failure (p = 0.0002),
stiffness (p = 0.0383), and work to failure (p = 0.0022) of
the degenerated tendons with uncoated sutures were ob-
served (Table 1).
Genipin-coated Sutures Increased Localized
Tissue Crosslinking
The level of fluorescence across groups (Fig. 5A) was
found to be different (p < 0.001). Mean fluorescence, that
indicates genipin-induced crosslinking (emission 590 nm,
excitation 645 nm), of the central part was higher in the
healthy (difference of means +12.26; standard error [SE],
1.23; 95% confidence interval [CI], 9.62-14.60; p < 0.001/
healthy genipin: mean 13.04; SD 0.78; 95% CI, 11.47-
14.62; p < 0.001) and degenerated (difference of means
+9.10; SE 1.21; 95% CI, 6.65-11.56; p < 0.001; degen-
erated genipin: mean 9.88; SD 0.75; 95% CI, 8.34-11.40;
p < 0.001) genipin-coated groups compared with the
healthy (mean 0.78; SD 0.95; 95% CI, -1.15 to 2.71; p =
0.44) and degenerated (mean 0.93; SD 0.75; 95% CI, -1.00
to 2.86; p = 0.36) control. A lower magnitude of fluores-
cence was observed in the degenerated genipin-coated
group compared with the healthy genipin-coated group
(difference of means. -3.16; SE 1.08; 95% CI, -5.34 to
-0.97; p = 0.006). No difference was observed between the
healthy control group and the collagenase-pretreated con-
trol group (difference of means -0.16; SE 1.36; 95% CI,
-2.57 to 2.88; p = 0.909).
As described in detail in the Methods, the longitudinal
distribution of fluorescence was analyzed by linear re-
gression. Accordingly, the regression coefficients are
reported that express fluorescence differences in percent-
age between the groups along the tendon. The relative
distribution of fluorescence along the tendon did not vary
between the healthy and degenerated genipin tendons (in
pullout direction: coefficient -0.2%, SE 7.0%; 95% CI,
-19.5% to 19.0%; p = 0.983; opposite direction: coefficient
-8.8%, SE 9.6% 95% CI, -10.4% to 28.0%, p = 0.364).
Fluorescence was unchanged in the pullout direction for
the healthy and degenerated genipin groups (coefficient
+10.5%; SE 7.1%; 95% CI, -3.4% to 24.4%; p = 0.135).
However, fluorescence decreased in the opposite direction
by 22.5% (SE 6.9%; 95% CI, 8.7%-36.4%; p = 0.002) for
healthy and degenerated genipin tendons, respectively.
Fig. 3 A-B (A) Suture pullout properties of the healthy and degenerated tendons and (B)
relative differences between genipin-treated and control tendons are shown. The white
bars show the values of tendons in the control group and the gray bars show the values of
the genipin-pretreated tendons. The whiskers represent minimum to maximum values. In
healthy tendons treated with genipin-coated sutures, a 60% improvement of pullout force
was observed (p = 0.0033). In degenerated tendons treated with genipin-coated sutures,
a 59% improvement of pullout force was observed (p = 0.0344).
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Absorption peaked at a wavelength of 590 nm for both
genipin groups (Fig. 5B). Therefore, the following ab-
sorption analyses were focused on a wavelength of 590 nm.
Both genipin groups absorbed more at 590 nm than the
control and degenerated tendons (Fig. 5C). In contrast to
the fluorescence results, the mean absorption of the healthy
genipin group (mean 16.65; SD 1.59; 95% CI, 13.44-
19.85; p > 0.001) was lower compared with the degen-
erated genipin group (difference of means -6.18; SE
2.19; 95% CI, -10.62 to -1.73; p = 0.008/degenerated
genipin: mean 22.82; SD 1.52; 95% CI, 19.74-25.90; p >
0.001). However, there was no difference in the relative
distribution of absorption between these groups along the
tendon. As described in the Methods in detail, the ab-
sorption distribution was analyzed by regression. For both
groups, absorption increased by 21.3% (SE 8.6%; 95% CI,
4.2%-38.4%; p = 0.015) in direction of suture pullout,
whereas there was a -53.7% (SE 8.1%; 95% CI, 70.8% to
-36.6%; p = 0.179) decrease toward the opposite end.
The fluorescent emission of the genipin-induced cross-
linking was also observed by fluorescence microscopy
(Fig. 6A-B), allowing qualitative assessment of the optical
spectral properties. The fluorescent signal intensity emitted
by the genipin-induced crosslinking was strongest in the
Fig. 4 A-D (A) Stiffness values of the healthy and degenerated tendons and (B) relative
differences are shown. The white bars show the values of tendons in the control group and
the gray bars show the values of the genipin-pretreated tendons. The whiskers represent
minimum to maximum values. No difference in stiffness of either the healthy or degen-
erated tendons was detected. (C) Work to failure values of the healthy and degenerated
tendons and (D) relative differences are shown. For healthy tendons, work to failure in-
creased (p = 0.015) but was not different in degenerated tendons.
Table 1. Mechanical properties of healthy and degenerated tendons treated with genipin-coated or untreated sutures
Mechanical
property
Healthy tendons Degenerated tendons
Control GP-coated
Difference
of medians p value* Control GP-coated
Difference
of medians p value*
Force to failure (N) 29 (13-48) 42 (24-73) 13 0.003 13 (5-28) 16 (9-36) 3 0.035
Stiffness (N/mm) 3.3 (1.1-9.6) 4.1 (2.3-8.1) 0.8 0.052 1.6 (0.5-5.6) 1.9 (0.7-13.4) 0.3 0.285
Work to failure (mJ) 148 (83-369) 275 (48-369) 127 0.025 53 (14-143) 75 (11-249) 22 0.636
All values are presented as medians (range).
*ratio paired t-test; GP = genipin.
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tissue area surrounding the genipin-coated suture (red box)
and slightly decreasing toward the ends of the tendon
sample.
Discussion
Suture cut-through constitutes the most common reason for
retear of arthroscopically performed rotator cuff tendon
repairs. Age-related alterations of the tendon tissue can
additionally lead to a reduction in suture retention strength.
Therefore, strategies to improve the structural resistance
to a suture complex are of interest. Genipin has shown
potential to augment resistance at the suture-tendon in-
terface for a simple stitch pattern [10]. A clinically feasible
method for localized and concentrated genipin delivery is
missing for possible in vivo preclinical evaluation. We
therefore investigated the potential of suture-based de-
livery of genipin to improve arthroscopic suture retention
in an in vitro model where tissue degeneration was induced
by collagenase before testing. In our study setting, genipin-
coated sutures increased force to failure in healthy and in
degenerated tendons.
This study had several limitations. First, ex vivo in-
jection of collagenase to induce collagen breakdown and
matrix disorganization was used to simulate degenerative
changes found in vivo [4, 7, 14, 18, 28]. Other biologic
changes found in tendinopathic specimens such as hyper-
cellularity and increased vascularity, however, are not
taken into account [45]. This enzymatic weakening of the
tendon was intended to mimic solely the structural features
found in degenerated human tendons and address the need
to consider age- and tissue quality-associated factors in
patients with tendon tears [13, 32, 36, 39, 46]. As such, the
collagenase pretreated control (uncoated suture) tendons
showed a lower maximum pullout force of -123%, lower
stiffness of -106%, and work to failure of -179% compared
with the untreated control group. Second, the study was
performed in an ex vivo bovine animal model. As a result
of potential interspecies differences in tendon properties,
caution is warranted when extrapolating these findings to
humans. In this ex vivo setting, the biologic response to
genipin treatment as well as long-term effects cannot be
studied. Third, the mechanical testing protocol does not
reflect the regime of high cyclic loading during daily ac-
tivities. However, during early rehabilitation after rotator
cuff repair, one involuntary movement of the arm can
overload the suture-tendon interface and lead to suture cut-
through [2]. Application of genipin is therefore aimed to
increase primary stability of the construct in the context of
a single precipitating event leading to a potential retear
rather than long-term tissue fatigue.
During arthroscopic surgery, a genipin-coated suture
would be exposed to flowing saline. A potential washout of
genipin during this period was not investigated and should
be the subject of future work. Once the suture is in place,
however,fluid flowduring arthroscopy at the suture segment
of interest would beminimal.We further tested a single loop
stitch, which is more practical in an arthroscopic setting than
Fig. 5 A-C Results of optical spectral properties. Fluorescence
and absorption are measured relative to the control group and
therefore have no unit. (A) Levels of genipin-induced crosslinking
fluorescence (emission 590 nm, excitation 645 nm) across the four
groups are shown parallel to suture pullout direction. The vertical
axis represents the distance in millimeters from the initial suture
position before pullout. The highest signal was recorded in the
healthy genipin group followed by the degenerated genipin
group. (B) The absorption of the tendon at the suture position
across different wavelengths (vertical axis) is shown. Peak ab-
sorption is measured at 590 nm for both genipin groups shown.
(C) The level of genipin-induced blue coloration at 590 nm is
shown parallel to suture pullout direction. The vertical axis rep-
resents the distance in millimeters from the initial suture position
before pullout. The healthy genipin group had a lower blue signal
compared with the degenerated genipin group.
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a more complex stitch configuration such as the modified
Mason-Allen, which had no relevant additional pullout re-
tention properties in combination with genipin [10].
A recent study showed that exogenous genipin collagen
crosslinking could increase median pullout force of a sin-
gle-loop stitch by > 30% in a highly simplified sheepmodel
of rotator cuff tendon repair [10]. This increase was
attained when the healthy ovine infraspinatus tendon was
incubated for 24 hours in a relatively high concentration
solution of genipin (20 mmol/L)—an approach that results
in substantial unintended crosslinking of the surrounding
tissue. Using the suture as a delivery vehicle is easily ap-
plicable and has been shown to be compatible with genipin
use [38]. We refined this approach, demonstrating that it
can be potentially relevant for a clinical application to
improve mechanical suture performance while minimizing
unintended tissue crosslinking.
A major aim of our study was to confirm effective local
delivery of genipin crosslinks to the tissue surrounding the
suture with a degree of crosslinking thought to be pro-
portional to the effective tensile strength of the tissue [8].
Quantification of the amount of genipin-induced collagen
crosslinking was performed using fluorescence measure-
ments at appropriate wavelengths [30, 35, 37]. Genipin-
related fluorescence decreased by 23% at a distance of
9 mm from the suture, suggesting reasonable localization
of genipin crosslinking. Degenerated tendon tissue showed
a lower level of genipin-specific fluorescence compared
with healthy tendon with no apparent qualitative difference
in distribution characteristics. The altered arrangement and
disorganized structure of fibrillary collagen by collagenase
treatment may reduce genipin-induced crosslinking. In
contrast, genipin-specific absorption generally was in-
creased in the collagenase-treated tissue, possibly attrib-
utable to the facilitated polymerization of genipin
molecules in higher molecular weight chains with the in-
creased presence of free amino acid ends [30, 35]. Using
a confocal microscope for a visual investigation of the
tendon, the fluorescent signal emitted by the genipin-
induced crosslinking was found to be high with the maxi-
mum intensity in the tissue surrounding the suture channel.
The tissue-augmenting effect of genipin in living ani-
mals has not yet been fully investigated. However, a recent
study showed collagen crosslinking to be highly persistent
1 year after intradermal genipin injection in horses [6]. That
study investigated the toxicologic effect of genipin with
good tolerability and no adverse effects.
Using an ex vivo animal model, we showed that suitable
genipin coating can increase suture retention strength in
healthy and degenerated bovine tendon. Fluorescence-
Fig. 6 A-B Confocal imaging of the genipin-induced crosslinking is shown. (A) Overall
scans of the tendon sample imaged with a spinning-disc confocal microscope are shown.
Collagen type I autofluorescence was imaged with a 405-nm laser excitation wavelength
(COL I) and genipin-induced crosslinking was imagedwith a 560-nm excitation wavelength
(GEN). The composite image (MERGED) shows the area with stronger crosslinks in the tissue
around the suture (red box). Blue indicates the genipin-induced crosslink signal was ar-
bitrarily chosen. Scale bar = 1.5 mm. (B) Enlargements of the area indicated by the yellow
box in A are shown. Scale bar = 0.25 mm.
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based analysis confirmed localization of genipin-induced
crosslinking at the margins of the delivery suture. This
study thus provides initial support that application of
genipin as a crosslinking agent to sutures may have clinical
utility in the arthroscopic repair of degenerated tendons.
Future studies might investigate the influence of genipin-
augmented sutures in vivo to study the tissue reaction to
a genipin-coated suture and to evaluate the effect over time.
Followup studies, especially in human tissue with a repair
stitch configuration, are needed for evaluation of a genipin-
coated suture toward a clinical application.
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